256
- Malaza A, Mossong J, Bärnighausen T, et al. Hypertension and obesity in adults living in a
high HIV prevalence rural area in South Africa. PLoS One. 2012;7:e47761. - de Jongh T, Gurol-Urganci I, Vodopivec-Jamsek V, et al. Mobile phone messaging
for facilitating self-management of long-term illnesses. Cochrane Database Syst Rev.
2012;12:CD007459. - Bray GA, Vollmer WM, Sacks FM, et al. A further subgroup analysis of the effects of the
DASH diet and three dietary sodium levels on blood pressure: results of the DASH-sodium
trial. Am J Cardiol. 2004;94:222–7. - Hall JE, Mizelle HL, Hildebrandt DA, et al. Abnormal pressure natriuresis. A cause or a
consequence of hypertension? Hypertension. 1990;15(6 Pt 1):547–59. - Sato A, Saruta T. Aldosterone-induced organ damage: plasma aldosterone level and inappro-
priate salt status. Hypertens Res. 2004;27:303–10. - Pimenta E, Gaddam KK, Pratt-Ubunama MN, et al. Relation of dietary salt and aldoste-
rone to urinary protein excretion in subjects with resistant hypertension. Hypertension.
2008;51:339–44. - Vogt L, Waanders F, Boomsma F, et al. Effects of dietary sodium and hydrochlorothiazide on
the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 2008;19:999–1007. - Krikken JA, Laverman GD, Navis G, et al. Benefits of dietary sodium restriction in the man-
agement of chronic kidney disease. Curr Opin Nephrol Hypertens. 2009;18:531–8. - Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hyper-
tension: association between resistant hypertension, aldosterone, and persistent intravascular
volume expansion. Arch Intern Med. 2008;168:1159–64. - Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment.
J Am Coll Cardiol. 2008;52:1749–57. - Messerli FH, Makani H, Benjo A, et al. Antihypertensive efficacy of hydrochlorothiazide as
evaluated by ambulatory blood pressure monitoring: ameta-analysis of randomized trials.
J Am Coll Cardiol. 2011;57:590–600. - Carter BL, Ernst ME, Cohen JD, et al. Hydrochlorothiazide versus chlorthalidone: evidence
supporting their interchangeability. Hypertension. 2004;43:4–9. - Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydro-
chlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension.
2006;47:352–8. - Moser M, Cushman W, Handler J. Resistant or difficult-to-treat hypertension. J ClinHypertens
(Greenwich). 2006;8:434–40. - Ernst ME, Gordon JA. Diuretic therapy: key aspects in hypertension and renal disease.
J Nephrol. 2010;23:487–93. - Jin J, Sklar GE, Min Sen Oh V, et al. Factors affecting therapeutic compliance: a review from
the patient’s perspective. Ther Clin Risk Manag. 2008;4:269–86. - Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease preven-
tion in clinical practice (version 2012). The fifth Joint task force of the European Society
of Cardiology and Other Societies on cardiovascular disease prevention in clinical prac-
tice (constituted by representatives of nine societies and by invited experts). Eur Heart
J. 2012;33:1635–701. - Muntner P, Mann D, Wildman RP, et al. Projected impact of polypill use among US adults:
medication use, cardiovascular risk reduction, and side effects. Am Heart J. 2011;161:719–25. - Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular preven-
tion: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med.
2009;6:101–10. - Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ.
2003;326:1419–23. - Zeymer U, Junger C, Zahn R, et al. Effects of a secondary prevention combination therapy
with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myo-
N. Keles et al.